Detalhe da pesquisa
1.
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Invest New Drugs
; 28(5): 641-9, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19572105
2.
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer.
Cancer Chemother Pharmacol
; 57(4): 540-4, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16193332
3.
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Clin Cancer Res
; 18(7): 2080-9, 2012 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22316603
4.
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Clin Cancer Res
; 17(3): 581-8, 2011 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21106728
5.
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Clin Cancer Res
; 16(22): 5564-72, 2010 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20926400
6.
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
Oncologist
; 10(3): 183-90, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15793221
7.
Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
Cancer
; 95(1): 147-54, 2002 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12115328